During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April-June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available.
Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023 / Fabiani, Massimo; Mateo-Urdiales, Alberto; Sacco, Chiara; Rota, Maria Cristina; Fotakis, Emmanouil Alexandros; Petrone, Daniele; Del Manso, Martina; Siddu, Andrea; Stefanelli, Paola; Bella, Antonino; Riccardo, Flavia; Rezza, Giovanni; Palamara, Anna Teresa; Brusaferro, Silvio; Pezzotti, Patrizio; Italian Integrated Surveillance of COVID-19 study group and of the Italian COVID-19 Vaccines Registry, Group. - In: EUROSURVEILLANCE. - ISSN 1560-7917. - 28:32(2023), pp. 1-7. [10.2807/1560-7917.ES.2023.28.32.2300397]
Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023
Fabiani, Massimo;Petrone, Daniele;Del Manso, Martina;Riccardo, Flavia;Palamara, Anna Teresa;Brusaferro, Silvio;
2023
Abstract
During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April-June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available.| File | Dimensione | Formato | |
|---|---|---|---|
|
Fabiani_Relative_2023.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
341.78 kB
Formato
Adobe PDF
|
341.78 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
